InterCure Ltd., manufacturer of the RESPeRATE hypertension treatment device, clinically-proven to significantly lower blood pressure, and a Challenge Fund II Portfolio Company,  today announced it sold its 100,000 RESPeRATE device during the 2007 holiday season. This milestone marks a period of widespread consumer adoption and physician support for the novel technology and provides strong momentum for the RESPeRATE launch into retail pharmacies planned later this year.

It took approximately 4 years to generate the first 50,000 unit sales of RESPeRATE, as clinical evidence, physician advocacy and consumer awareness began to take hold following the OTC clearance of the device. The second 50,000 units were sold in just 15 months. Growth is being driven through increased traction in the U.S. direct-to-consumer and online retail channels.

"InterCure is experiencing robust growth in our core direct-to-consumer and online retail businesses. This reflects the growing consumer adoption rate for the RESPeRATE  device and will serve us well as we expand our distribution into chain drugstores," said Erez Gavish, president and CEO of InterCure, manufacturer of the RESPeRATE device.